ATM and breast cancer: For example, overtreatment may result when care providers offer risk-reducing mastectomy (RRM) to female RPPV carriers with or without a BC diagnosis, even though their risks may be similar to carriers of PVs in moderate penetrance genes such as ATM or CHEK2 for which RRM is not recommended68.